Study on effect of Fufang Xueshuantong capsule on serpine1,α-serpine1 protein and KLF2 in patients with lower extremity venous thrombosis
- VernacularTitle:复方血栓通胶囊对下肢静脉血栓患者血清纤溶serpine1、α－serpine1蛋白及KLF2影响研究
- Author:
Changlin ZHANG
;
Yong XIANG
;
Ande LIU
;
Jinghao XU
;
Wu LUO
;
Shuangyou LONG
- Publication Type:Journal Article
- Keywords:
Fufang Xueshuantong capsule;
lower extremity venous thrombosis;
fibrinolysis system
- From:
Chinese Journal of Biochemical Pharmaceutics
2015;37(7):110-112
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the effect of serpine1, α-serpine1 protein and KLF2 in patients with lower extremity venous thrombosis by Fufang Xueshuantong capsule.Methods 44 patients were diagnosed with lower extremity venous thrombosis were collected, and randomly divided into experimental group and control group, 22 cases in each group, giving the conventional antiplatelet therapy, on the basis of this, the experimental group was given Fufang Xueshuantong capsule 1.5 g, three times a day orally, and the control group was given context Shutong granules 20 g, three times a day orally.2 weeks for a course of treatment, three courses of treatment.Before and after treatment in the detection of two groups of patients with serum serpine1, α-serpine1 KLF2 and protein contents, blood rheology, coagulation function, and carries on the analysis.ResuIts Compared with the control group, experimental group patients has better curative effect, the performance of: serum serpine1and α-serpine1 protein content were significantly decreased(P<0.05).KLF2 expression was significantly higher (P<0.05).Blood viscosity, erythrocyte aggregation index, erythrocyte sedimentation rate decreased significantly (P<0.05).Fib, D-D content significantly decreased (P<0.05).ConcIusions Fufang Xueshuantong capsule can reduce serum serpine1, α-serpine1 protein content and promote KLF2 expression, decrease the blood viscosity, erythrocyte sedimentation rate, improve patients with hypercoagulable state in patients with lower extremity venous thrombosis, so as to achieve good clinical efficacy.
